Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 879M 766M 710M 664M 1.25B 82.93B 1.25B 8.42B 3.26B 40.82B 3.3B 3.23B 142B P/E 2026 *
-5.82x
P/E 2027 * -5.38x
Enterprise Value 770M 671M 621M 582M 1.09B 72.61B 1.1B 7.37B 2.86B 35.74B 2.89B 2.83B 124B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.15%
Yield 2026 *
-
Yield 2027 * -
1 week+9.46%
Current month+1.46%
1 month+8.68%
3 months-22.10%
6 months+6.70%
Current year+6.70%
1 week 6.71
Extreme 6.708
7.69
1 month 6.31
Extreme 6.306
7.71
3 years 3.7
Extreme 3.7
14.9
5 years 2.2
Extreme 2.2
21.2
Manager TitleAgeSince
Chief Executive Officer 47 07/05/2018
Director of Finance/CFO 52 01/09/2019
Chief Tech/Sci/R&D Officer - 18/08/2025
Director TitleAgeSince
Chairman 68 07/03/2018
Director/Board Member 47 07/05/2018
Director/Board Member 62 01/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.11%+9.46%-7.98%+26.93% 879M
+1.44%-0.23%+63.66%+112.12% 54.44B
+4.60%+5.82%+56.35%+43.04% 45.8B
-1.44%+1.51%-12.94%-19.24% 22.98B
-2.69%-0.95%-3.68%+379.00% 20.76B
+3.22%+2.94%+24.02%-35.05% 16.25B
+0.58%+1.24%+15.53%-38.87% 15.34B
-1.01%-2.97%+27.42%+171.92% 13.05B
+3.07%+5.43%+21.37% - 12.37B
+4.95%+13.49%+121.11%+249.05% 12.47B
Average +1.41%+2.19%+30.49%+98.77% 23.72B
Weighted average by Cap. +1.63%+1.38%+39.31%+97.58%

Financials

2026 *2027 *
Net sales - -
Net income -155M -136M -126M -118M -220M -14.67B -222M -1.49B -577M -7.22B -584M -571M -25.07B -186M -162M -150M -140M -263M -17.54B -265M -1.78B -690M -8.63B -698M -683M -29.97B
Net Debt -109M -95.32M -88.28M -82.64M -155M -10.32B -156M -1.05B -406M -5.08B -410M -402M -17.63B -231M -202M -187M -175M -328M -21.83B -330M -2.22B -859M -10.74B -868M -850M -37.31B
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
-
Date Price Change
19/06/26 7.280 -1.11%
18/06/26 7.362 -1.55%
17/06/26 7.478 +4.35%
16/06/26 7.166 +0.06%
15/06/26 7.162 -0.14%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
8.490USD
Average target price
20.29USD
Spread / Average Target
+138.94%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!